Biologicals and hematopoietic cytokines in prevention or treatment of infections in immunocompromised hosts.
The number of immunocompromised hosts has dramatically increased in recent years. The primary reason for this increase has been the intensification of antineoplastic therapy for the treatment of various malignancies and the explosive spread of human immunodeficiency virus infection. Although the treatment and prevention of many infections have been improved with the rational use of antimicrobial agents, ultimate success can be blunted by protracted impairment of essential host defenses or by the virulence of certain organisms.
Roilides
E
E
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Pizzo
P A
PA
D016207:Cytokines / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D016867:Immunocompromised Host; D007239:Infections / Q000188:drug therapy*; D007371:Interferon-gamma / Q000627:therapeutic use; D007375:Interleukin-1 / Q000627:therapeutic use; D016173:Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D014611:Vaccination
D016207:Cytokines; D007375:Interleukin-1; D016179:Granulocyte Colony-Stimulating Factor; D016173:Macrophage Colony-Stimulating Factor; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor